Medical device company ResMed (NYSE:RMD) met Wall Street’s revenue expectations in Q1 CY2025, with sales up 7.9% year on year ...

ResMed Inc. (ASX: RMD) shares are having a strong finish to the week. Here's why investors are buying this blue chip ...

Shares edge higher; Trump to reportedly wind down tariff rate on China; Tesla leaps 5pc; ResMed evades trade war blow; iron ...

A decent finish to the week is expected for Aussie investors. The post 5 things to watch on the ASX 200 on Thursday appeared ...

Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder.

Discover ResMed's Q3 2025 earnings highlights, including 8% revenue growth, margin expansion, new product launches, and strategic investments in ...

Resmed beat Wall Street estimates for third-quarter profit on Wednesday, driven by demand for its sleep apnea devices used to manage the common sleep disorder. The company manufactures continuous ...

Unveiled the findings of our fifth annual Global Sleep Survey. With insights from 30,026 respondents across 13 markets, the study underscored a widespread global sleep crisis, with people losing an ...

SAN DIEGO (AP) — SAN DIEGO (AP) — ResMed Inc. (RMD) on Wednesday reported fiscal third-quarter profit of $365 million. On a per-share basis, the San Diego-based company said it had profit of $2.48.